All News

Breast cancer often forges unlikely friendships via internet connections.

A rock band made up of gynecologic oncologists is connecting with patients and their fans through rock music.

The Internet is abundant with ads for cancer cures that seem too good to be true. How should patients and consumers navigate this overflow of information?

A new combination, including the immunotherapy agent Keytruda, was shown to be highly effective in treating a subset of patients with myeloma.

A recent study found that the preferred way to hear cancer stories and connect with other patients is via online forums.

CTL019, a CAR T-cell therapy, had a high response rate for young patients with relapsed/refractory ALL in a recent phase 2 study.

It is impossible for this patient to thank just one nurse as the third year in treatment gets underway.

Immunotherapy combinations are on the horizon for the treatment of renal cell carcinoma, Robert J. Motzer, M.D., says.

Eight individuals were honored for their dedication to MPN at the 2016 MPN Heroes™ celebration.

A novel agent showed a 78 percent response rate for patients with relapsed/refractory multiple myeloma, according to a recent phase 1 study.

A phase 2 study is examining Keytruda in combination with two other agents for treatment of ovarian cancer.

Cooling caps to prevent chemothreapy-related hair loss are gaining popularity in the United States.

Are electronic cigarettes less harmful than traditional cigarettes? A upcoming study is looking to find out.

Recent-onset diabetes can lead to poorer outcomes in pancreatic cancer, according to a recent study.

A week of surfing at cancer camp.

A recently launched clinical trial is exploring a new agent to treat patients with advanced, recurrent, platinum-resistant ovarian cancer.

The House of Representatives just passed the 21st Century Cures Act, providing over $6 billion for health initiatives.

Keytruda was granted a priority review to a supplemental biologics license application (sBLA) to treat a subset of patients with classical Hodgkin lymphoma.

One company's production of a popular bladder cancer therapy is set to halt by mid-2017, generating worries from patients and oncologists that there will be a shortage.

With the addition of PARP inhibitors, as well as new agents on the horizon, the treatment landscape of gynecologic cancers is progressing.

I actively encourage all my clients experiencing life-altering stressors to trick the mind using the art of reframing.

Six-year breast cancer survivor is still unhappy with brain fog, even this far out from chemotherapy treatments.

The combination of Opdivo and Yervoy is showing promise in the treatment of bladder cancer, according to a recent study.

A combination of topical drugs may reduce lesions that eventually grow into cancer, according to a recent study.

The National LGBT Cancer Network is making cancer screenings more available to a high-risk, underserved population.

Some of the leading nonprofits in the field are teaming together to improve the lives of patients with lung cancer.

In the future, entrectinib may play an increasing role in the treatment of brain tumors, as well as other cancers.

A panel of experts recently discussed the evolving field of immunotherapy for solid tumor types.

Immunotherapy continues to advance in melanoma and other solid tumor types as new combinations and biomarkers are being explored.

I really don't understand why some of us bear heavier burdens than others....